Vascular-targeting agent
A vascular-targeting agent or vascular disrupting agent is a drug designed to damage the vasculature of cancer tumors causing central necrosis.
VTAs can be small-molecule or ligand-based.
Small-molecule VTAs include:
- microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate, ZD6126, AVE8062, Oxi 4503
- vadimezan
Clinical trials
Phase II : ZD6126, CA4P, plinabulinPhase III : DMXAA.